Skip to main content

Link to Smithsonian homepage

Smithsonian Music

Main menu

  • Calendar
  • Listen
  • Learn
    • Ask Smithsonian
    • Collections Spotlights
    • Music Stories
  • Watch
  • Blog

Digitalis Purpurea

Object Details

Description
This specimen is one of approximately 187 specimens of materia medica (crude drug material) representing plants introduced and employed by physicians of the Eclectic School of American practitioners. In the early 1920s, the Smithsonian developed three small exhibits on the so-called "alternative" schools of medicine: homeopathy, osteopathy, and eclectic medicine. In 1924, John Uri Lloyd (1849-1936) procured these specimens for the museum's eclectic medicine exhibit.
The Eclectic School, which emerged in the United States in the 1830s, arose from earlier botanical medicine movements and Native American herbal traditions. Practitioners primarily used plant-based drugs that were indigenous to the United States and developed a distinct "American materia medica." Lloyd Brothers, established in 1886 by brothers John Uri Lloyd, Curtis Gates Lloyd (1859-1926), and Nelson Ashley Lloyd (1851-1925), was a major supplier of quality botanical drugs for the eclectic physician.
Location
Currently not on view
Data Source
National Museum of American History
maker
Lloyd Brothers
Credit Line
Accession 71753 (1924); Gift of Lloyd Brothers; selected by Dr. John Uri Lloyd
Physical Description
foxglove (overall material)
Measurements
overall: 4 1/2 in x 2 in; 11.43 cm x 5.08 cm
Object Name
Crude Drug
Other Terms
Crude Drug; Materia Medica; Drugs; Vegetable; Leaf
There are restrictions for re-using this image. For more information, visit the Smithsonian's Terms of Use page .
International media Interoperability Framework
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.
View manifest View in Mirador Viewer

Link to Smithsonian homepage

  • About
  • Terms of Use
  • Privacy
  • YouTube
  • Twitter
Back to Top